JP2023523218A5 - - Google Patents
Info
- Publication number
- JP2023523218A5 JP2023523218A5 JP2022563971A JP2022563971A JP2023523218A5 JP 2023523218 A5 JP2023523218 A5 JP 2023523218A5 JP 2022563971 A JP2022563971 A JP 2022563971A JP 2022563971 A JP2022563971 A JP 2022563971A JP 2023523218 A5 JP2023523218 A5 JP 2023523218A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- cancer
- weeks
- storage
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013801P | 2020-04-22 | 2020-04-22 | |
| US63/013,801 | 2020-04-22 | ||
| PCT/IB2021/053254 WO2021214658A1 (en) | 2020-04-22 | 2021-04-20 | Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523218A JP2023523218A (ja) | 2023-06-02 |
| JP2023523218A5 true JP2023523218A5 (enExample) | 2024-04-30 |
Family
ID=75639945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563971A Pending JP2023523218A (ja) | 2020-04-22 | 2021-04-20 | ヘテロ二量体ヒトインターロイキン－１５（ｈｅｔＩＬ－１５）の医薬組成物及び医薬製品 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210330747A1 (enExample) |
| EP (1) | EP4138782A1 (enExample) |
| JP (1) | JP2023523218A (enExample) |
| KR (1) | KR20230004655A (enExample) |
| CN (1) | CN115443127A (enExample) |
| AR (1) | AR122428A1 (enExample) |
| AU (1) | AU2021260989A1 (enExample) |
| BR (1) | BR112022020973A2 (enExample) |
| CA (1) | CA3178895A1 (enExample) |
| CO (1) | CO2022014867A2 (enExample) |
| IL (1) | IL297326A (enExample) |
| MX (1) | MX2022013352A (enExample) |
| TW (1) | TW202214290A (enExample) |
| WO (1) | WO2021214658A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7083206B2 (ja) | 2019-06-28 | 2022-06-10 | 国立大学法人 東京大学 | タンパク質内包高分子ミセル |
| EP4434998A4 (en) * | 2021-11-18 | 2025-06-18 | Shandong Simcere Biopharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION OF IL-15 MUTANT FUSION PROTEIN |
| KR20250144433A (ko) * | 2023-02-14 | 2025-10-10 | 아크론 바이오프로덕츠 엘엘씨 | 생체내 이용을 위한 인터루킨 제형물 |
| CN117883565A (zh) * | 2023-12-25 | 2024-04-16 | 中山大学 | 沙美特罗和pd-1抗体联用在制备治疗黑色素瘤的药物中的应用 |
| WO2025206413A1 (en) * | 2024-03-28 | 2025-10-02 | The University Of Tokyo | Protein-enclosing polymeric complexes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| EP1984505B1 (en) | 2006-01-13 | 2019-12-25 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| EP2249809A1 (en) * | 2008-01-15 | 2010-11-17 | Abbott GmbH & Co. KG | Powdered protein compositions and methods of making same |
| CN102099221B (zh) | 2008-08-22 | 2014-01-29 | 麦格纳座椅公司 | 具有减小空转的盘形调角器 |
| KR101746881B1 (ko) * | 2009-10-21 | 2017-06-14 | 오웬 멈포드 리미티드 | 오토인젝터 |
| EP2619229B1 (en) | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| BR122021025267B1 (pt) * | 2013-02-22 | 2023-12-05 | Curevac Ag | Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1 |
| WO2016018920A1 (en) * | 2014-07-29 | 2016-02-04 | Admune Therapeutics Llc | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
| WO2017177063A1 (en) * | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
| PL3639845T3 (pl) * | 2017-07-25 | 2023-10-23 | Jiangsu Hengrui Medicine Co., Ltd. | Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania |
| CA3102821A1 (en) * | 2018-06-22 | 2019-12-26 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| KR20220005028A (ko) * | 2019-04-26 | 2022-01-12 | 루비우스 테라퓨틱스, 아이엔씨. | 탈핵 적혈구를 포함하는 조성물 |
-
2021
- 2021-04-20 IL IL297326A patent/IL297326A/en unknown
- 2021-04-20 US US17/234,914 patent/US20210330747A1/en active Pending
- 2021-04-20 KR KR1020227040050A patent/KR20230004655A/ko active Pending
- 2021-04-20 BR BR112022020973A patent/BR112022020973A2/pt unknown
- 2021-04-20 EP EP21720852.9A patent/EP4138782A1/en active Pending
- 2021-04-20 CN CN202180030326.7A patent/CN115443127A/zh active Pending
- 2021-04-20 JP JP2022563971A patent/JP2023523218A/ja active Pending
- 2021-04-20 WO PCT/IB2021/053254 patent/WO2021214658A1/en not_active Ceased
- 2021-04-20 TW TW110114219A patent/TW202214290A/zh unknown
- 2021-04-20 AU AU2021260989A patent/AU2021260989A1/en active Pending
- 2021-04-20 MX MX2022013352A patent/MX2022013352A/es unknown
- 2021-04-20 CA CA3178895A patent/CA3178895A1/en active Pending
- 2021-04-22 AR ARP210101082A patent/AR122428A1/es unknown
-
2022
- 2022-10-19 CO CONC2022/0014867A patent/CO2022014867A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102864931B1 (ko) | 인간화 항-전립선 특이적 막 항원(psma) 항체 약물 접합체 | |
| ES2706428T3 (es) | Inmunoconjugado de IL-12 | |
| ES2633453T3 (es) | Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos | |
| CN111328346B (zh) | 基于人铁蛋白和蛋白酶可切割肽的融合蛋白及其作为化学治疗载体的用途 | |
| ES3031307T3 (en) | Proteins binding nkg2d, cd16 and egfr | |
| ES2774296T3 (es) | Terapias de combinación para tratar cánceres quimiorresistentes | |
| JP2005508981A5 (enExample) | ||
| JP2010047601A (ja) | カハラリドｆ | |
| RU2017146657A (ru) | Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона | |
| US20110124564A1 (en) | Nucleolin-binding peptides, nucleolin- binding lytic peptides, fusion constructs and methods of making and using same | |
| KR20230010221A (ko) | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 | |
| JP2020509737A5 (enExample) | ||
| CN103347514B (zh) | Fgfr1胞外域组合疗法 | |
| TW201907947A (zh) | 一種ｉｌ－１５蛋白質複合物醫藥組成物及其用途 | |
| ES2674491T3 (es) | Nuevos fragmentos de anticuerpos, composiciones y usos de los mismos | |
| JP7660523B2 (ja) | アルカリリン酸塩に基づいた癌治療 | |
| JP2004512370A5 (enExample) | ||
| ES2930351T3 (es) | Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante | |
| WO2024153224A1 (zh) | 一种含艾日布林衍生物药物偶联物的药物组合物 | |
| EP3996680B1 (en) | Stable formulations of recombinant proteins | |
| JP2023553562A (ja) | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 | |
| CN116710114A (zh) | Glp-1/glp-2双重激动剂的药物组合物 | |
| AU2015216941B2 (en) | Polypeptide fragments of 168A-T2 and compositions comprising them for use in treating cancer | |
| JP2023512337A (ja) | インターロイキン－１２とフィブロネクチンのエクストラドメインｂに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 | |
| WO2024179453A1 (zh) | 重组人源化抗Nectin-4单抗-MMAE偶联药物的药物组合物 |